» Articles » PMID: 29156731

MiR-21 Modulates the Effect of EZH2 on the Biological Behavior of Human Lung Cancer Stem Cells

Overview
Journal Oncotarget
Specialty Oncology
Date 2017 Nov 22
PMID 29156731
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Non-small-cell lung cancer has a high mortality rate and poor prognosis. Therefore, novel therapeutic approaches are urgently needed to enhance patient survival rates. In this study, we investigated the effects of miR-21 and EZH2 on the biological behavior of human lung cancer stem cells . We found increased expression of EZH2 and miR-21 in LCSCs, and miR-21 overexpression increased EZH2 levels in LCSCs. In addition, EZH2 and miR-21 knockdown increased the sensitivity of LCSCs to chemo- and radiation therapy, and exogenous EZH2 expression rescued the effects of anti-miR-21. Cell proliferation was reduced by 39.2% and 69.7% in the presence of radio or chemotherapy combined with anti-miR-21 transfection, respectively. The downstream molecules included Cdc2, cyclin B1, and Bcl-2, which are involved in the regulation of cell cycle and apoptosis and which could themselves be reduced or enhanced by changes in miR-21 and EZH2 levels in LCSCs. This study demonstrates the direct relationship between miR-21 and EZH2 which was increased by 43% after the application of the miR-21 mimic. Above data indicates that these two molecules can influence the biological behavior of LCSCs by altering their corresponding targets. Our findings support the potential roles of miR-21 and EZH2 in improving the therapeutic efficacy of clinical lung cancer treatments.

Citing Articles

Exploring the therapeutic potential of targeting polycomb repressive complex 2 in lung cancer.

Gao M, Li Y, Cao P, Liu H, Chen J, Kang S Front Oncol. 2023; 13:1216289.

PMID: 37909018 PMC: 10613995. DOI: 10.3389/fonc.2023.1216289.


Integrated multi-omics analyses and functional validation reveal TTK as a novel EMT activator for endometrial cancer.

Miao Y, Konno Y, Wang B, Zhu L, Zhai T, Ihira K J Transl Med. 2023; 21(1):151.

PMID: 36829176 PMC: 9960418. DOI: 10.1186/s12967-023-03998-8.


Contingent Synergistic Interactions between Non-Coding RNAs and DNA-Modifying Enzymes in Myelodysplastic Syndromes.

Symeonidis A, Chatzilygeroudi T, Chondrou V, Sgourou A Int J Mol Sci. 2022; 23(24).

PMID: 36555712 PMC: 9785516. DOI: 10.3390/ijms232416069.


Comprehensive analysis of chemokines family and related regulatory ceRNA network in lung adenocarcinoma.

Hu Y, Xiao M, Zhang D, Shen J, Zhao Y, Li M Heliyon. 2022; 8(11):e11399.

PMID: 36387469 PMC: 9650007. DOI: 10.1016/j.heliyon.2022.e11399.


Revisiting the miR-200 Family: A Clan of Five Siblings with Essential Roles in Development and Disease.

Sundararajan V, Burk U, Bajdak-Rusinek K Biomolecules. 2022; 12(6).

PMID: 35740906 PMC: 9221129. DOI: 10.3390/biom12060781.


References
1.
Stella G, Luisetti M, Pozzi E, Comoglio P . Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics. Lancet Respir Med. 2014; 1(3):251-61. DOI: 10.1016/S2213-2600(13)70009-2. View

2.
Vella S, Pomella S, Leoncini P, Colletti M, Conti B, Marquez V . MicroRNA-101 is repressed by EZH2 and its restoration inhibits tumorigenic features in embryonal rhabdomyosarcoma. Clin Epigenetics. 2015; 7:82. PMC: 4527101. DOI: 10.1186/s13148-015-0107-z. View

3.
Seymour T, Nowak A, Kakulas F . Targeting Aggressive Cancer Stem Cells in Glioblastoma. Front Oncol. 2015; 5:159. PMC: 4507454. DOI: 10.3389/fonc.2015.00159. View

4.
Kuykendall A, Chiappori A . Advanced EGFR mutation-positive non-small-cell lung cancer: case report, literature review, and treatment recommendations. Cancer Control. 2013; 21(1):67-73. DOI: 10.1177/107327481402100110. View

5.
Leon G, MacDonagh L, Finn S, Cuffe S, Barr M . Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways. Pharmacol Ther. 2015; 158:71-90. DOI: 10.1016/j.pharmthera.2015.12.001. View